Taysha Gene Therapies
TSHA
208 hedge funds and large institutions have $2.06B invested in Taysha Gene Therapies in 2026 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 98 increasing their positions, 41 reducing their positions, and 22 closing their positions.
366% more call options, than puts
Call options by funds: $5.15M | Put options by funds: $1.1M
281% more capital inflows, than outflows
Capital inflows: $281M | Capital outflows: $73.8M
139% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 41
86% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 22
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
11.78% more ownership
Funds ownership: 92.47% → 104.25% (+12%)
9% more funds holding
Funds holding: 191 → 208 (+17)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$26.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$19.8M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$16.3M |
| 4 |
BlackRock
New York
|
+$13.8M |
| 5 |
Farallon Capital Management
San Francisco,
California
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deerfield Management
New York
|
-$12.2M |
| 2 |
SG Americas Securities
New York
|
-$11.7M |
| 3 |
Morgan Stanley
New York
|
-$8.75M |
| 4 |
Barclays
London,
United Kingdom
|
-$6.99M |
| 5 |
Millennium Management
New York
|
-$6.83M |
TSHA Hedge Fund Activity: Q2 2026 in Review
208 of the 8,353 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q2 2026, worth a combined $2.06B — up 71% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new TSHA positions and 22 closed out — a net gain of 19 holders — while 98 added to existing stakes and 41 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $26.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $12.2M sold.
- 208 institutional investors held Taysha Gene Therapies (TSHA) as of Q2 2026, up from 191 in Q1 2026.
- Funds reported $2.06B of Taysha Gene Therapies stock for Q2 2026, up 71% quarter-over-quarter.
- 41 funds opened new Taysha Gene Therapies positions in Q2 2026 and 22 closed out, a net change of +19 holders.
- The largest Taysha Gene Therapies buyer in Q2 2026 was MPM BioImpact, an estimated $26.6M added.
- The largest Taysha Gene Therapies seller in Q2 2026 was Deerfield Management, an estimated $12.2M sold.
Based on aggregated 13F filings for Q2 2026.